Global /China /Healthcare /Biotechnology /3378

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378

• SHEK: 3378 • Delayed

31.70HKD -0.9%

4.05 USD

As of 15 June 2026, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has a market cap of $555.84M USD, ranking #14428 globally and #4462 in China. It ranks #1285 in the Healthcare sector, and #240 in the Biotechnology industry.

Global Rank

14428

Country Rank

4462

Sector Rank

1285

Industry Rank

240

Key Stats

Market Cap

$555.84MUSD

4.36B HKD

Enterprise Value

$478.33MUSD

3.75B HKD

Revenue (TTM)

$13.06KUSD

102.38K HKD

EBITDA (TTM)

-$20.33MUSD

-159.27M HKD

Net Income (TTM)

-$18.6MUSD

-145.79M HKD

PS Ratio

42550.5

PB Ratio

5.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Qixiang Li open_in_new

Employees

Founded

2014

Website

hanxbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.9%	1.1%	11%	85%	-7.1%	100%	-7.1%	-7.1%	-7.1%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	3378 ISIN: CNE100007C34 Shares Out.: Shares Outstanding: 136.219M¹ Shares Float: 27.598M² TV: TradingView: HKEX: 3378 SA: Stock Analysis: HKG: 3378 YF: Yahoo Finance: 3378.HK GF: Google Finance: HKG: 3378 BA: Barron's: 3378 MS: Morningstar: XHKG: 03378	31.70 HKD	TV: TradingView: HKEX: 3378 SA: Stock Analysis: HKG: 3378 YF: Yahoo Finance: 3378.HK GF: Google Finance: HKG: 3378 BA: Barron's: 3378 MS: Morningstar: XHKG: 03378

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases. The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways. The company was incorporated in 2014 and is headquartered in Wuhan, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 3K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 2K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 1K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 1K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 1K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 1K%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 33K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 29K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 9K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 8K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 8K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 8K%	37.2	Switzerland

chevron_leftBack